leisure time -WSS

leisure time

author：fashion 2025-09-02 17:36:02 - browse：24436

A psilocybin mushroom lays inside a clear capsule — Adobe

A single dose of psilocybin may have enduring benefits for people with major depressive disorder, according to a randomized clinical trial published Thursday in the Journal of the American Medical Association.

Several prior studies have suggested that psilocybin, the psychedelic compound produced by certain types of mushrooms, could be a promising way to treat major depression in people for whom antidepressants or counseling aren’t effective. But those studies mostly focused on short-term results, while the new JAMA study looked at psilocybin’s efficacy up to six weeks after the administration of a single dose of psilocybin.

“It’s exciting to see another study that’s coming out that is adding to the evidence base suggesting potential efficacy of psilocybin for depression, amongst other conditions,” said Greg Fonzo, an assistant professor and co-director for the Center for Psychedelic Research and Therapy at the University of Texas at Austin’s Dell Medical School, who was not involved in the study.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： WHO recommends second malaria vaccine

focus

WSS

Setback for rare diseases as Taysha Gene Therapies pulls back

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Study finds gene variants tied to breast cancer risk in Black women

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

WHO recommends second malaria vaccine

H5N1 virus can be tracked in retail milk, scientists say

focus

leisure time

hotspot

Medical leaders decry Supreme Court decision on affirmative action

Congress extends some pandemic preparedness programs

Medical leaders decry Supreme Court decision on affirmative action

Digital health: a case of mistaken identity

Moonlake's readout produced a cash windfall. Risks remain

Some top drug companies are starting to take action on climate

DIEP, the 'gold standard' of breast reconstruction, is under threat

What we owe ALS patients — and why one company fell short

Anesthesiologist group: stop taking Ozempic before surgery

Health insurers' Q3 question: how much care are people getting?

focus

Experts study whether long Covid risk adds up with each reinfection

Some top drug companies are starting to take action on climate

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

The Karikó problem: Lessons for funding basic research

Will an HIV vaccine ever be a reality?

focus

leisure time

focus

focus